Financhill
Back

vTv Therapeutics Quote, Financials, Valuation and Earnings

vTv Therapeutics Price Quote

$25.74
+0.24 (+0.94%)
(Updated: May 9, 2024 at 11:00 AM ET)

vTv Therapeutics Key Stats

Buy
65
vTv Therapeutics (VTVT) is a Buy

Day range:
$25.00 - $25.98
52-week range:
$7.38 - $39.60
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%

Volume:
5.2K
Avg. volume:
7.2K
1-year change:
-18.29%
Market cap:
$60.1M
Revenue:
$0
EPS:
$-9.71

How Much Does vTv Therapeutics Make?

Data Unavailable

Is vTv Therapeutics Growing As A Company?

Data Unavailable

vTv Therapeutics Stock Price Performance

  • Did vTv Therapeutics Stock Go Up Last Month?
    vTv Therapeutics share price went up by 2% last month
  • Did VTVT's Share Price Rise Over The Last Year?
    VTVT share price fell by -18.29% over the past 1 year

What Is vTv Therapeutics 52-Week High & Low?

vTv Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy vTv Therapeutics?

  • How Much Debt Does vTv Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does vTv Therapeutics Have?
    Cash and short term investments quarterly total is $9.4M
  • What Is vTv Therapeutics’s Book Value Per Share?
    Book value per share is -11.84

Is vTv Therapeutics Cash Flow Positive?

  • What Is VTVT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$19.1M
  • What Is vTv Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $12M
  • What Is vTv Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

vTv Therapeutics Return On Invested Capital

Data Unavailable

vTv Therapeutics Earnings Date & Stock Price

vTv Therapeutics Competitors

  • Who Are vTv Therapeutics's Competitors?
    Below is a list of companies who compete with vTv Therapeutics or are related in some way:
    • Altimmune Inc (ALT)
    • G1 Therapeutics Inc (GTHX)
    • Oragenics Inc (OGEN)
    • Palatin Technologies Inc (PTN)
    • Viking Therapeutics Inc (VKTX)

vTv Therapeutics Dividend Yield

Data Unavailable

vTv Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 25%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 80.00
Upside from Last Price: 213.73%

Major Shareholders

  • How many VTVT shares are owned by institutional investors?
    1.9M VTVT shares are owned by institutional investors
  • How many VTVT shares are owned by insiders?
    280.2K VTVT shares are owned by insiders